Market Overview - On March 28, 2025, A-shares closed with all three major indices declining, with the Shanghai Composite Index down 0.67% at 3351.31 points, the ChiNext Index down 0.79% at 2128.21 points, and the STAR 50 Index down 1.07% at 1029.48 points. The total trading volume in the Shanghai and Shenzhen markets was 1.12 trillion yuan, a decrease of 71.7 billion yuan from the previous trading day [2] - Hong Kong stocks opened high but closed lower, with the Hang Seng Index down 0.65% or 152.2 points at 23426.6 points, and a total trading volume of 229.62 billion HKD. The Hang Seng China Enterprises Index fell 0.82% to 8606.51 points, while the Hang Seng Tech Index dropped 1.48% to 5506.47 points. For the week, the Hang Seng Index fell 1.11%, the China Enterprises Index fell 1.55%, and the Tech Index fell 2.36% [2] - On the same day, U.S. stocks saw all three major indices rise, with the S&P 500 up 1.59% at 5954.5 points, the Nasdaq Composite up 1.63% at 18847.28 points, and the Dow Jones Industrial Average up 1.39% at 43840.91 points [2] New Stock Offerings - Two new stocks are available for subscription today: Taihe Co., Ltd. (Code: 301665) with an issue price of 10.27 yuan per share and a price-to-earnings ratio of 13.4 times, primarily engaged in the research, production, and sales of pesticide products and functional chemicals [3] - The second stock, Xinkai Technology (Code: 001335), has an issue price of 12.8 yuan per share and a price-to-earnings ratio of 14.38 times, focusing on the research, production, and sales of organic pigments and acid dyes, with applications in inks, coatings, and plastics [3] Important News - On March 30, 2025, four major banks in China, including Bank of China, China Construction Bank, Bank of Communications, and Postal Savings Bank, announced plans to issue A-shares to introduce strategic investment from the Ministry of Finance, with a total amount of 500 billion yuan. Specifically, Bank of China plans to raise up to 165 billion yuan, China Construction Bank up to 105 billion yuan, Bank of Communications up to 120 billion yuan, and Postal Savings Bank up to 130 billion yuan [4][5] - The China Securities Regulatory Commission (CSRC) has announced a ban on investors participating in IPO strategic placements from lending shares during the lock-up period, aiming to strengthen the management of listed companies and ensure compliance with regulations [5] Industry Insights - The Vice Minister of Industry and Information Technology, Xin Guobin, stated on March 29, 2025, that the ministry will focus on several key areas to address "involution" in the automotive industry, including enhancing technological breakthroughs, accelerating the industrialization of autonomous driving, and promoting digital transformation across the entire industry chain [6][7] - The ministry plans to compile a new growth plan for the automotive industry, implement policies to stabilize and expand automotive consumption, and support the development of intelligent connected vehicles, including conditional approval for L3 autonomous driving vehicle production [7]

Core Viewpoint - The article discusses the upcoming IPOs of two companies, Taihe Co., Ltd. and Xinkai Technology, highlighting their business models, financial performance, and investment plans. Group 1: Taihe Co., Ltd. - Taihe Co., Ltd. is a leading supplier of agricultural fungicides and herbicides in China, with a strong market presence and technological capabilities [2][3] - The company plans to issue shares at a price of 10.27 CNY per share, with a maximum subscription limit of 7,000 shares per account, requiring a market value of 70,000 CNY in the Shenzhen market for full subscription [3] - Taihe's revenue for 2022, 2023, and 2024 is projected to be 5.099 billion CNY, 3.868 billion CNY, and 4.214 billion CNY, respectively, with net profits of 649 million CNY, 346 million CNY, and 261 million CNY [3][4] - The funds raised will be invested in fungicide projects and a research and development center, including the production of various active ingredients [4] Group 2: Xinkai Technology - Xinkai Technology is a core supplier in the global organic pigment market, recognized as the top exporter of organic pigments in China for several consecutive years [2][5] - The company will issue shares at a price of 12.8 CNY per share, with a maximum subscription limit of 9,000 shares per account, requiring a market value of 90,000 CNY in the Shenzhen market for full subscription [5] - Xinkai's revenue for 2022, 2023, and 2024 is projected to be 1.192 billion CNY, 1.069 billion CNY, and 1.417 billion CNY, respectively, with net profits of 88 million CNY, 88 million CNY, and 111 million CNY [6] - The funds raised will be used for the construction of a research and development center and headquarters, as well as to repay bank loans [7]

Core Viewpoint - Taihe Co., Ltd. is set to go public with an issuance price of 10.27 yuan per share, focusing on the research, production, and sales of pesticide products and functional chemicals [1] Group 1: Business Overview - Taihe Co., Ltd. specializes in the development, production, and sales of pesticide products and functional chemicals, emphasizing the principle of maintaining a continuous technological advantage in its products [1] - The company's core products include significant market leaders such as the fungicide pyraclostrobin, the herbicide 2,4-D, and the protective fungicide chlorothalonil, with pyraclostrobin being the world's largest fungicide and 2,4-D being the largest herbicide of its kind [1] - Taihe has established long-term strategic partnerships with multinational companies like Syngenta, Dow, and Honeywell, with exports covering major markets in South America, North America, Southeast Asia, and Europe [1] Group 2: Financial Performance - From 2021 to the first half of 2024, Taihe's operating revenues were 3.579 billion yuan, 5.099 billion yuan, 3.868 billion yuan, and 1.959 billion yuan, while net profits attributable to the parent company were 398 million yuan, 649 million yuan, 346 million yuan, and 106 million yuan respectively [2] - Research and development expenditures during the same period were 121 million yuan, 181 million yuan, 149 million yuan, and 61.016 million yuan [2] Group 3: Strategic Initiatives - The company aims to enhance the production capacity of its key product, pyraclostrobin, and scale up the production of newly developed pesticide raw materials, while also establishing a research and development center [3] - These initiatives are expected to diversify the product range, optimize product structure, and strengthen innovation in products and technology, thereby consolidating and enhancing the company's market position and overall competitiveness [3]

Core Viewpoint - The company reported a decline in revenue and net profit for 2024, with a significant drop in the agricultural pesticide market expected to recover in 2025 [1][2][3]. Financial Performance - The company achieved revenue of 7.31 billion yuan in 2024, a year-on-year decrease of 6.9% - Net profit attributable to shareholders was 220 million yuan, down 64.3%, with earnings per share at 0.27 yuan, aligning with market expectations - In Q4 2024, revenue reached 2.12 billion yuan, a year-on-year increase of 15.1%, while net profit was 83 million yuan, up 89.9% [1]. Industry Trends - The price of glyphosate continues to decline, with the average price in 2024 at 54,300 yuan per ton, a 34% decrease from 2023 - In Q1 2025, the average price is approximately 45,900 yuan per ton, reflecting a year-on-year decrease of 24.3% and a quarter-on-quarter decrease of 6.6% - The future competition may hinge on the efficiency of refined glyphosate, with potential cost reduction opportunities [1][2]. Strategic Developments - The company plans to acquire Shandong Huimeng to strengthen its position in refined glyphosate and fungicides - Shandong Huimeng has advanced technologies in DCTF and refined glyphosate production, which could enhance the company's competitive edge in the pesticide market - The global agricultural pesticide market, after a significant downturn in 2024, is expected to stabilize and grow in 2025, driven by improved weather conditions and increased planting areas in the U.S. and Brazil [2]. Profit Forecast and Valuation - The company has adjusted its 2025 net profit forecast down by 12.9% to 563 million yuan and introduced a 2026 net profit forecast of 702 million yuan - The current stock price corresponds to a P/E ratio of 13x for 2025 and 11x for 2026 - The target price is maintained at 10.0 yuan, suggesting a 9% upside potential based on the current valuation [3].

Core Viewpoint - Lier Chemical's 2024 annual performance shows a significant decline in revenue and profit, indicating ongoing challenges in the pesticide industry due to intense competition and market conditions [1][2]. Financial Performance - Revenue for 2024 was 7.311 billion yuan, a year-on-year decrease of 6.87% - Profit was 215 million yuan, down 64.34% year-on-year, marking the lowest profit level since 2017 - Gross margin was 16.06%, compared to 23.34% in the previous year [1]. Market Conditions - The pesticide industry has not shown significant recovery in 2024, with continued intense competition and most pesticide product prices remaining at low levels - Market inventory is gradually returning to normal, but overall supply exceeds demand, impacting industry development [1]. - The price for glyphosate raw materials is reported at 47,000 yuan/ton, while refined glyphosate raw materials are priced at 72,000 yuan/ton [1]. International Sales - International sales revenue for 2024 was 3.437 billion yuan, accounting for 47.01% of total revenue - This represents a decline from 6.158 billion yuan (60.76% of total revenue) in 2022 and 3.958 billion yuan (50.42% of total revenue) in 2023 [2]. Shareholder Information - The company plans to implement a profit distribution plan of "10 for 2 yuan (including tax)" for a total dividend of 160 million yuan - Shanghai Yuanhong Investment Management Co., Ltd. has become the seventh largest shareholder with 5.3327 million shares, valued at approximately 49.11 million yuan [3]. Future Outlook - The company anticipates significant adjustments in the supply structure of the industry, with opportunities arising from supply contraction and the introduction of new products - The global pesticide market is expected to show steady growth due to increasing food demand driven by population growth and the rapid development of genetically modified crops [3].

Group 1 - China Telecom reported a net profit of 33.01 billion yuan for 2024, an increase of 8.4% year-on-year, with total revenue of 523.57 billion yuan, up 3.1% [1] - Minfeng Special Paper achieved a net profit of 72 million yuan, a year-on-year increase of 54.09%, despite a revenue decline of 9.82% to 1.46 billion yuan [2] - Kuaiji Elevator's net profit decreased by 8.46% to 132 million yuan, with total revenue falling by 4.93% to 1.58 billion yuan [3] Group 2 - Zhongjian Technology reported a net profit of 356 million yuan, up 23.16% year-on-year, with total revenue of 812 million yuan, an increase of 45.39% [4] - China Communication Technology announced the resignation of Vice President Zhao Xiaodong due to work changes [6] - Honghua Digital received a warning letter from the Zhejiang Securities Regulatory Bureau for failing to disclose the use of idle raised funds in a timely manner [8] Group 3 - Huazhong Shuanghe received a drug registration certificate for Gadobutrol injection, applicable for MRI examinations [10] - Ruihe Co. reported overdue loans totaling 15.2 million yuan due to slow accounts receivable turnover caused by a major client's debt crisis [12] - Lubo Chemical received a dividend of 76.5 million yuan from its subsidiary [13] Group 4 - Sihai Visual plans to use up to 500 million yuan of idle funds to purchase low-risk, short-term financial products [14] - Binjiang Group won the land use rights for two plots at a total price of 7.742 billion yuan [16] - Canan Co. received a utility model patent certificate for a needle sheath feeding mechanism [18] Group 5 - David Medical's subsidiary's medical device registration application was accepted by the Zhejiang Provincial Drug Administration [20] - Rejing Bio obtained 30 overseas qualification certifications for various in vitro diagnostic reagents and instruments [22] - Jincheng Mining signed a contract worth approximately 21.5 million USD for infrastructure support at a Zambian mine [24] Group 6 - Baiyun Mountain's subsidiary received approval for clinical trials of a new herbal tea product [26] - Hunan Haili successfully acquired land use rights for two plots in Yongxing County [28] - Nanshan Aluminum's subsidiary was listed on the Hong Kong Stock Exchange [30] Group 7 - Jinghua New Materials' application for a simplified procedure to issue shares was accepted by the Shanghai Stock Exchange [32] - Ningbo Construction filed a lawsuit for overdue project payments totaling 112 million yuan [34] - Tiantong Co. received a government subsidy of 47.52 million yuan [36] Group 8 - Zhongqi Co. appointed Zhang Zipeng as the new general manager [38] - Ruihu Mold reported a net profit of 350 million yuan, up 73.20% year-on-year, with total revenue of 2.424 billion yuan [40] - Mega Chip reported a net profit of 211 million yuan, a year-on-year increase of 26.30%, with total revenue of 2.139 billion yuan [42] Group 9 - Shenhuo Co. reported a net profit of 4.307 billion yuan, a decrease of 27.07% year-on-year, with total revenue of 38.373 billion yuan [44] - Feikai Materials plans to acquire 100% of JNC Suzhou and related patents for a total consideration of 3.7 billion yuan [46] - Junpu Intelligent announced that its major shareholders committed not to reduce their holdings for 12 months [48] Group 10 - Yaxing Anchor Chain confirmed that its production and operations are normal amid market interest in marine economy concepts [50] - Guangzhou Development plans to invest 5.612 billion yuan in a coal power environmental replacement project [52] - Ruihu Mold intends to issue convertible bonds to raise up to 880 million yuan for various projects [54]

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company's performance is under pressure due to declining pesticide prices, with a revenue decrease of 9.09% year-on-year to 10.435 billion yuan and a net profit drop of 23.19% to 1.202 billion yuan in 2024 [1][4] - The company has completed the first phase of the Yuchuang project, producing qualified products, which positions it to benefit from the anticipated recovery in the agricultural protection industry [3][4] Summary by Sections Financial Performance - In 2024, the company achieved revenue of 10.435 billion yuan, a decrease of 9.09% year-on-year, and a net profit of 1.202 billion yuan, down 23.19% year-on-year [1] - The average selling prices for raw materials and formulations fell by 16.0% and 9.4%, respectively, leading to a revenue decline in both segments [2] - The raw material business generated revenue of 6.418 billion yuan, down 13.1%, while the formulation business brought in 1.545 billion yuan, down 7.8% [2] Project Development - The Yuchuang Phase I project in Liaoning has been completed and is in the process of trial production, with several products already meeting quality standards [3] - As of the end of 2024, the company has invested 2.78 billion yuan in the Yuchuang project, accounting for 80% of the total budget [3] Market Outlook - The agricultural protection industry is currently in a low prosperity state, but there are signs of recovery as inventory levels normalize and supply-demand dynamics improve [3] - The company is expected to benefit from the overall recovery in the agricultural protection sector as it is a leading player in the domestic pesticide industry [3][4] Profit Forecast and Valuation - The profit forecasts for 2025-2027 have been adjusted downward due to the ongoing low price environment for pesticide products, with expected net profits of 1.378 billion yuan, 1.625 billion yuan, and 1.910 billion yuan for those years, respectively [4][5] - The report highlights that the company's product structure will be further enhanced with the full completion of the Yuchuang project, supporting the "Buy" rating [4]

独立董事 2024 年度述职报告 李晨 扬农化工: 独立董事2024年度述职报告（李晨） 江苏扬农化工股份有限公司 一、独立董事基本情况 （一）个人工作履历、专业背景以及兼职情况 本人李晨，为法律专业人士，在律师事务所从事律师职业多年，现为北京大 成（南京）律师事务所律师、高级合伙人、执行主任。2022 年 6 月起任扬农化工 独立董事。 （二）在扬农化工董事会专门委员会的任职情况 公司董事会下设审计委员会、薪酬与考核委员会、提名委员会和战略委员 会，我分别担任审计委员会委员、薪酬与考核委员会委员和提名委员会委员。 （三）独立性情况的说明 作为扬农化工的独立董事，我不存在《上市公司独立董事管理办法》第六条 所述情形，不存在影响独立性的情况。 二、独立董事年度履职概况 （一）出席董事会及专门委员会情况 本年应参加董 出席现场会议 以通讯方式 委托出席 缺席 事会次数 （次） 参加（次） （次） （次） 《公司章程》 （六）与中小股东沟通情况 及《董事会议事规则》的规定和要求，出席了全部董事会会议，认真审议议案， 并以严谨的态度行使表决权，充分发挥了独立董事的作用，维护了公司的整体利 益和中小股东的利益。我认为公 ...

Group 1: Financial Performance - In 2024, the company achieved a sales structure improvement contributing $53 million for the year and $17 million in Q4 [2] - The overall sales revenue for 2024 showed a year-on-year decline, but the decline in the overall plant protection market was similar, indicating no loss of market share for the company [2] - The company's EBITDA and profit margins improved year-on-year, with Q4 sales showing a 2% increase when excluding currency effects [3] Group 2: Product Development and Market Strategy - The new product introduction rate for 2023 and 2024 was 22%, with no improvement in 2024, reflecting challenges in differentiated product sales [1] - The company is committed to launching new products and enhancing its sales team's capabilities to focus on high-value products [2] - The company strategically decided to reduce focus on volatile-priced products, opting instead for value-innovative products [3] Group 3: Regional Sales Insights - North America was the only region to show year-on-year growth in agricultural business despite a shrinking market size [2] - The company maintains a cautious approach to selling bulk plant protection products, focusing on those that contribute positively to overall profitability [3] Group 4: Cost Management and Operational Efficiency - The "Advancement" plan aims to optimize financial health and reduce costs, although it has led to increased sales and management expenses due to restructuring costs [4] - The company reported a $68 million reduction in operating expenses when excluding special items related to the "Advancement" plan [4] Group 5: Market Challenges and Opportunities - The potential impact of U.S. tariffs on the supply chain is uncertain, but the company believes its diversified production locations mitigate risks [5] - The "One Certificate, One Product" policy is expected to benefit the company's formulation products, although the price outlook remains under pressure [6]

Financial Data and Key Metrics Changes - In Q4 2024, gross profit increased by 14% and EBITDA rose by 45% compared to the same period last year [10][11] - Full year EBITDA for 2024 was 15% higher than 2023, marking one of the few companies in the industry to show growth in EBITDA [10][11] - Sales for Q4 2024 decreased by 2% to $1.1 billion, but at constant exchange rates (CER), they increased by 2% [15] - Full year sales declined by 11% to $4.1 billion, with an 8% decrease in CER [17][19] - The company achieved a gross margin of 25.6% in 2024, up from 22.7% in 2023 [18][19] Business Line Data and Key Metrics Changes - The company experienced a significant improvement in gross profit and EBITDA margins due to better cost management and a favorable product mix [15][19] - The sales volume remained stable, but pricing pressures led to an overall decline in sales [17][19] Market Data and Key Metrics Changes - In North America, the company saw a growth in sales despite a declining market, attributed to strategic deals with major distributors [68][69] - Latin America experienced a 4% increase in local currency sales, but an 8% decline in dollar terms due to currency impacts [22][26] - Asia Pacific saw a decline of 6-7% in sales, influenced by strategic decisions to align sales closer to the agricultural season [22][23] Company Strategy and Development Direction - The company is focused on a "Fight Forward" transformation plan aimed at improving financial health and operational efficiency [34][36] - The strategy includes centralizing corporate functions, optimizing geographical presence, and focusing on high-value products while exiting low-profit markets [41][42][43] - The company aims to enhance its competitive position in the value innovation segment, targeting growers seeking innovation at acceptable prices [47][48] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing pressure on grower profitability and overcapacity in the market, particularly from Chinese producers [7][8] - Despite challenges, the company is optimistic about maintaining momentum into 2025, supported by improved performance metrics in Q4 2024 [75] - The management emphasized the importance of strategic decisions to walk away from low-profit products to focus on value innovation [72][73] Other Important Information - The company reduced its inventory significantly, from $2.4 billion at the end of 2022 to $1.05 billion in 2024, reflecting efficient inventory management [32] - Operating cash flow improved to $528 million, with free cash flow reaching $364 million, higher than the previous year [30][31] Q&A Session Summary Question: Recent price trends of pesticides and market demand - Management indicated that while some active ingredients have seen price increases, the majority remain at historical lows due to overproduction [60][63] Question: Stability of NPI rate and performance of differentiated products - The stable NPI rate reflects ongoing R&D investment, with improvements in sales of differentiated products noted in Q4 [64][65][66] Question: Regional sales performance and North America outlook - Management clarified that while overall sales declined, North America saw growth due to strategic partnerships, maintaining market share [68][69] Question: Impact of Bayer's potential withdrawal from glyphosate market - Management refrained from commenting on competitors but reiterated their strategic focus on high-value products [72] Question: Potential rebound in sales and profits for 2025 - Management did not provide specific guidance but expressed optimism based on Q4 performance improvements [75] Question: Effectiveness of the Fight Forward plan amid rising expenses - Management explained that increased expenses are due to one-time costs related to restructuring and transformation initiatives [76][77] Question: Future business outlook amid U.S. tariff increases - Management acknowledged the challenges posed by tariffs but emphasized the company's diversified production footprint as a mitigating factor [78][84] Question: Implementation of the one product or one registration policy in China - Management is preparing for the policy's implementation, expecting opportunities for growth through differentiated product innovation [86][87] Question: Guidance on short and mid-term targets for expense reduction - Management reiterated that they do not provide guidance but are focused on optimizing operational costs [88] Question: Status of management structure adjustments - Management confirmed that the transformation process is ongoing, with a focus on enhancing competitive strategies and KPIs [89][90]